



Centre for  
Public Health

# **Merseyside Inter Agency Drug Misuse Database**

**January– March 2007**

**Wirral DAAT**

**Quarter 4 2006/07**

**Esther Shepherd, Martin Chandler,  
Jim McVeigh**

**DRAFT REPORT**

The final version will be available on the IAD website

[www.cph.org.uk/iad](http://www.cph.org.uk/iad)

Acknowledgements:

The Authors would like to thank the following for their valuable contributions to the production of this report: Paul Duffy, Adam Marr, Simon Russell and Claire Shaw.

We would also like to thank the data providers for their efforts in assisting and maintaining the monitoring process.

Contacts:

Martin Chandler  
IAD Manager  
Centre for Public Health  
Faculty of Health & Applied Social Sciences  
Liverpool John Moores University  
Castle House  
North Street  
L3 2AY

(0151) 231 4531

[m.chandler@ljmu.ac.uk](mailto:m.chandler@ljmu.ac.uk)

Esther Shepherd

IAD Researcher

(0151) 231 4521

[e.shepherd@ljmu.ac.uk](mailto:e.shepherd@ljmu.ac.uk)

[www.cph.org.uk/iad](http://www.cph.org.uk/iad)

# Contents

	<b><u>Page</u></b>
<b>Introduction</b>	<b>1</b>
<b>Arrest Referral</b>	<b>3</b>
Table 1: Individuals assessed, by Gender and Age Group	
Table 2: Year to Date, by Gender and Age Group	
Table 3: Reported Main Drug(s) of Use, by Frequency of Use	
<b>Probation</b>	<b>5</b>
<b>Syringe Exchange Services</b>	<b>6</b>
<b>Agency</b>	
Table 4: Individuals by Gender	
Table 5: Individuals by Gender: Steroid Users Omitted	
Table 6: Individuals by Age Group	
Table 7: Individuals by Age Group: Steroid Users Omitted	
Table 8: Gender by Age Group of Individuals	
Table 9: Gender by Age Group: Steroid Users Omitted	
Table 10: Year to Date, by Gender & Age Group	
Table 11: Year to Date, by Gender & Age Group: Steroid Users Omitted	
Table 12: Year to Date, by Gender & Age Group: Steroid Users Only	
Table 13: Main Drug of Use for New Agency Syringe Exchange Clients, by Gender	
Table 14: Main Drug of Use, for New Agency Syringe Exchange Clients, by Age Group	
<b>Pharmacy</b>	<b>11</b>
Table 15: Individuals by Gender	
Table 16: Individuals by Age Group	
Table 17: Year to Date, by Gender & Age Group	
<b>Combined</b>	<b>12</b>
Table 18: Individuals in Syringe Exchange, by Gender	
Table 19: Individuals in Syringe Exchange, by Gender: Steroid Users omitted	
Table 20: Individuals in Syringe Exchange, by Age Group	
Table 21: Individuals in Syringe Exchange, by Age Group: Steroid Users omitted	
Table 22: Year to Date, by Gender & Age Group	
Table 23: Total Syringes Provided	

## **National Drug Treatment Monitoring System (NDTMS) 14**

Table 24: Individuals in contact with Treatment Services, by Gender

Table 25: Year to Date, by Gender

Table 26: Individuals in contact with Treatment Services, by Age Group

Table 27: Year to Date, by Age Group

Table 28: Ethnicity of Individuals in Contact with Treatment Services

Table 29: Individuals in contact with Treatment Services, by Main Drug of Use

## **Connexions 17**

Table 30: Individuals in Contact with Connexions, by Gender

Table 31: Year to Date, by Gender

Table 32: Individuals in Contact with Connexions, by Age

Table 33: Year to Date, by Age

Table 34: Individuals in Contact with Connexions by Drug/Alcohol Problem

Table 35: Year to Date, by Drug/Alcohol Problem

## **Combined Datasets 19**

Table 36: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Table 37: Year to Date, by Gender & Age Group

## **Cross Matched Datasets 20**

Fig 1: Crossover between Agency Syringe Exchange and NDTMS datasets

Fig 2: Crossover between Pharmacy Syringe Exchange and NDTMS datasets

## Introduction

The Inter Agency Drug Misuse Database (IAD), established by Merseyside Drug (and Alcohol) Action Teams, Merseyside Police and the Public Health Sector (now Centre for Public Health) in 1997, supports the need for local information on drug misuse. In particular the IAD aims to:

- Provide comprehensive reporting of problem drug users' (PDUs') characteristics including a range of demographics and the types of drugs used.
- Reflect levels of service and intervention activity.
- Assist in D(A)AT's (and other responsible bodies) performance management.
- Facilitate the planning and development of services and interventions for PDUs.
- Identify gaps in service provision and delivery, as well as under-served groups as specified by the National Treatment Agency and Department of Health and by the Centre for Public Health, through interrogation of available data.
- Highlight changes in levels, demographics and characteristics of drug user populations.
- Report back to both individual D(A)ATs and service providers in the form of audits and quarterly reports as well as responding to ad hoc requests.
- Provide summary reporting on an annual basis.

To enable the above the IAD collects data from as many agencies in contact with drug users as possible and is continually seeking to expand the range and scope of data providers. Data are currently collected from criminal justice services, needle exchange schemes (both pharmacy and agency-based), the National Drug Treatment Monitoring System (NDTMS) and Connexions (young people).

### Data considerations

Analysis of data depends on the provision of attributable information. Each service provider records first and last initials, date of birth and gender, for each individual they record a contact with. The combination of these details provides an identifier (attributor) for each individual (e.g.: HF07/12/1974M). This is a nationally recognised system and allows individuals to be tracked through different service providers and across time whilst retaining an acceptable degree of anonymity. The attributor is essential to avoid double counting of individuals both within and across datasets, as well as enabling us to match across datasets. The D(A)AT referred to is the D(A)AT of contact unless otherwise stated.

The IAD will *only* be reporting attributable data for each dataset. In the past, report deadlines have been missed due to data arriving too late to be cleaned and analysed in time, or more often because the data requires a great deal of cleaning and validation before analysis. These reports are useful only if they can arrive within timelines useful to D(A)ATs (ie: in time for NTA quarterly submissions). For this reason, reports will now be sent out according to a strict timetable, with each quarter's report to be sent in the first week of the third month following the close of the reporting period. Any data that is missing or non-attributable will not be included in the report.

Year-to-Date figures will be provided for the current financial year, and will incorporate updated figures from previous quarters. The figures are calculated by aggregating successive quarterly datasets to omit double counting of those who present to services in each quarter. Year-to-Date data will be the most accurate reflection of annual service activity and will override previous quarterly data.



The Centre for Public Health will continue to work closely with service providers and D(A)ATs in order to improve both the timeliness and quality of monitoring data provided to the IAD. Many service providers are turning to electronic recording of data and it is hoped this will vastly improve the quality of the data as systems improve.

**ARREST REFERRAL (AR)****Quarter 4 (2006/07)****Introduction**

Raw data are provided by the Drug Intervention Programme (DIP) Team based at the Centre for Public Health, Liverpool John Moores University. The data supplied are for validated contacts within specified D(A)AT areas and are aggregated to one person per D(A)AT area. Individuals may therefore appear more than once within the final dataset if they have been seen in more than one D(A)AT area, but only once for each D(A)AT area within the reporting period.

**Table 1: Individuals assessed, by Gender & Age Group**

<b>Gender</b>	<b>n</b>	<b>%</b>
Male	127	83.0
Female	26	17.0
<b>Age Group</b>		
Under 18	0	0
18-19	14	9.2
20-24	30	19.6
25-29	27	17.6
30-34	18	11.8
35-39	31	20.3
40-44	23	15.0
45+	10	6.5
<b>Total</b>	<b>153</b>	<b>100</b>

**Table 2: Year to Date, by Gender & Age Group**

	<b>Gender</b>				<b>Total in Age Group</b>	
	<b>Male</b>		<b>Female</b>			
<b>Age Group</b>	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>
Under 18	2	0.5	0	0	2	0.4
18-19	45	11.1	3	3.4	48	9.7
20-24	74	18.2	8	9.2	82	16.6
25-29	53	13.1	14	16.1	67	13.6
30-34	74	18.2	13	14.9	87	17.6
35-39	76	18.7	31	35.6	107	21.7
40-44	51	12.6	13	14.9	64	13.0
45+	31	7.6	5	5.7	36	7.3
<b>Total</b>	<b>406</b>	<b>100</b>	<b>87</b>	<b>100</b>	<b>493</b>	<b>100</b>

**Table 3: Reported Main Drug(s) of Use, by Frequency of Use**

Drug of Use	Daily	Weekly
Amphetamines	1	1
Benzodiazepines	3	2
Cannabis	31	20
Crack	23	16
Cocaine	12	31
Ecstasy	0	5
Heroin	40	18
Methadone	16	4

**NB:** The complexity of the drug profiles reported through arrest referral is such that we have decided the best way of reporting the data is to provide figures for the number of people reporting Daily or Weekly use of each drug. Where "Main drug" is provided in the original data it does not always match the other substances reported as being used daily; consequently, this method of reporting should provide a more accurate picture of drug use as reported through Arrest Referral rather than simply stating the "Main Drug". However it should be noted that some people may report several drugs being used and will therefore be counted in the figures for each drug they report. For this reason totals are not provided.

## **PROBATION**

### **Quarter 4 (2006/07)**

#### **Introduction**

Due to last minute technical problems it was not possible to include Probation data for this quarter. The Annual Report will however, include data from Quarter 4 2006/07.

## SYRINGE EXCHANGE SERVICES

Quarter 4 (2006/07)

### Introduction

Data are collected directly from syringe exchange providers. Analysis of syringe exchange data allows performance monitoring of harm reduction services at both D(A)AT and service provider level.

### AGENCY SYRINGE EXCHANGE

**Table 4: Individuals by Gender**

<b>New Clients</b>	<b>n</b>	<b>%</b>
Male	38	97.4
Female	1	2.6
<i>Total</i>	39	100
<b>All Clients</b>		
Male	260	92.2
Female	22	7.8
<i>Total</i>	282	100

**Table 5: Individuals by Gender: Steroids Users Omitted**

<b>New Clients</b>	<b>n</b>	<b>%</b>
Male	14	93.3
Female	1	6.7
<i>Total</i>	15	100
<b>All Clients</b>		
Male	115	84.6
Female	21	15.4
<i>Total</i>	136	100

Table 6: Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0	1	0.4
18-19	6	15.4	18	6.4
20-24	14	35.9	50	17.7
25-29	5	12.8	36	12.8
30-34	6	15.4	43	15.2
35-39	4	10.3	59	20.9
40-44	2	5.1	41	14.5
45+	2	5.1	34	12.1
<b>Total</b>	<b>39</b>	<b>100</b>	<b>282</b>	<b>100</b>

Table 7: Individuals by Age Group: Steroid Users Omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0	1	0.7
18-19	0	0	3	2.2
20-24	5	33.3	7	5.1
25-29	1	6.7	7	5.1
30-34	5	33.3	18	13.2
35-39	2	13.3	46	33.8
40-44	1	6.7	27	19.9
45+	1	6.7	27	19.9
<b>Total</b>	<b>15</b>	<b>100</b>	<b>136</b>	<b>100</b>

Table 8: Gender by Age Group of Individuals

Age Group	Gender			
	Male		Female	
	n	%	n	%
Under 18	1	0.4	0	0
18-19	18	6.9	0	0
20-24	50	19.2	0	0
25-29	34	13.1	2	9.1
30-34	39	15.0	4	18.2
35-39	52	20.0	7	31.8
40-44	37	14.2	4	18.2
45+	29	11.2	5	22.7
<b>Total</b>	<b>260</b>	<b>100</b>	<b>22</b>	<b>100</b>

Table 9: Gender by Age Group: Steroid Users Omitted

Age Group	Gender			
	Male		Female	
	n	%	n	%
Under 18	1	0.9	0	0
18-19	3	2.6	0	0
20-24	7	6.1	0	0
25-29	5	4.3	2	9.5
30-34	15	13.0	3	14.3
35-39	39	33.9	7	33.3
40-44	23	20.0	4	19.0
45+	22	19.1	5	23.8
<b>Total</b>	<b>115</b>	<b>100</b>	<b>21</b>	<b>100</b>

Table 10: Year to Date, by Gender &amp; Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	10	1.6	0	0	10	1.5
18-19	53	8.3	0	0	53	7.7
20-24	137	21.3	1	2.2	138	20.1
25-29	98	15.3	6	13.3	104	15.1
30-34	112	17.4	9	20.0	121	17.6
35-39	97	15.1	14	31.1	111	16.2
40-44	83	12.9	9	20.0	92	13.4
45+	52	8.1	6	13.3	58	8.4
<b>Total</b>	<b>642</b>	<b>100</b>	<b>45</b>	<b>100</b>	<b>687</b>	<b>100</b>

Table 11: Year to Date, by Gender &amp; Age Group: Steroid Users Omitted

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	1	0.4	0	0	1	0.4
18-19	6	2.5	0	0	6	2.1
20-24	10	4.1	1	2.4	11	3.9
25-29	14	5.8	5	12.2	19	6.7
30-34	49	20.2	6	14.6	55	19.4
35-39	66	27.3	14	34.1	80	28.3
40-44	59	24.4	9	22.0	68	24.0
45+	37	15.3	6	14.6	43	15.2
<b>Total</b>	<b>242</b>	<b>100</b>	<b>41</b>	<b>100</b>	<b>283</b>	<b>100</b>

Table 12: Year to Date, by Gender &amp; Age Group: Steroid Users Only

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	9	2.3	0	0	9	22.2
18-19	47	11.8	0	0	47	11.6
20-24	127	31.8	0	0	127	31.4
25-29	84	21.0	1	25.0	85	21.0
30-34	63	15.8	3	75.0	66	16.3
35-39	31	7.8	0	0	31	7.7
40-44	24	6.0	0	0	24	5.9
45+	15	3.8	0	0	15	3.7
<b>Total</b>	<b>400</b>	<b>100</b>	<b>4</b>	<b>100</b>	<b>404</b>	<b>100</b>

Table 13: Main Drug of Use for New Agency Syringe Exchange Clients, by Gender

Drug of Use	Gender			
	Male		Female	
	n	%	n	%
Heroin	3	7.9	1	100
Steroids	24	63.2	0	0
Unknown	11	28.9	0	0
<b>Total</b>	<b>38</b>	<b>100</b>	<b>1</b>	<b>100</b>

**Please Note:** Due to changes in reporting methods we will now only report drug of use for new clients. Information on drug of use for all clients is available on request.

Table 14: Main Drug of Use for New Agency Syringe Exchange Clients, by Age Group

Age Group	Heroin		Steroids		Unknown	
	n	%	n	%	n	%
	Under 18	0	0	0	0	0
18-19	0	0	6	100	0	0
20-24	0	0	9	64.3	5	35.7
25-29	0	0	4	80.0	1	20.0
30-34	2	33.3	1	16.7	3	50.0
35-39	1	25.0	2	50.0	1	25.0
40-44	0	0	1	50.0	1	50.0
45+	1	50.0	1	50.0	0	0
<b>Total*</b>	<b>4</b>	<b>10.3</b>	<b>24</b>	<b>61.5</b>	<b>11</b>	<b>28.2</b>

\* % Totals are by Drug, not Age Group

## PHARMACY SYRINGE EXCHANGE

**Table 15: Individuals by Gender**

<b>New Clients</b>	<b>n</b>	<b>%</b>
Male	50	83.3
Female	10	16.7
<i>Total</i>	<i>60</i>	<i>100</i>
<b>All Clients</b>		
Male	151	84.8
Female	27	15.2
<i>Total</i>	<i>178</i>	<i>100</i>

**Table 16: Individuals by Age Group**

<b>Age Group</b>	<b>New Clients</b>		<b>All Clients</b>	
	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>
Under 18	0	0	0	0
18-19	2	3.3	3	1.7
20-24	4	6.7	5	2.8
25-29	6	10.0	14	7.9
30-34	13	21.7	33	18.5
35-39	21	35.0	50	28.1
40-44	11	18.3	43	24.2
45+	3	5.0	30	16.9
<i>Total</i>	<i>60</i>	<i>100</i>	<i>178</i>	<i>100</i>

**Table 17: Year to Date, by Gender & Age Group**

<b>Age Group</b>	<b>Gender</b>				<b>Total in Age Group</b>	
	<b>Male</b>		<b>Female</b>			
	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>
Under 18	0	0	0	0	0	0
18-19	8	2.	0	0	8	2.2
20-24	10	3.1	3	5.8	13	3.5
25-29	34	10.6	4	7.7	38	10.2
30-34	63	19.7	15	28.8	78	21.0
35-39	86	26.9	14	26.9	100	26.9
40-44	69	21.6	11	21.2	80	21.5
45+	50	15.6	5	9.6	55	14.8
<i>Total</i>	<i>320</i>	<i>100</i>	<i>52</i>	<i>100</i>	<i>372</i>	<i>100</i>

## COMBINED PHARMACY AND AGENCY SYRINGE EXCHANGE

Analyses here are based on an aggregated combination of Agency and Pharmacy-based datasets for the reporting period. Data are aggregated by attributor and D(A)AT to one person per D(A)AT area.

**Table 18: Individuals in Syringe Exchange, by Gender**

New Clients	n	%
Male	88	88.9
Female	11	11.1
<i>Total</i>	99	100
All Clients		
Male	400	89.5
Female	47	10.5
<i>Total</i>	447	100

**Table 19: Individuals in Syringe Exchange, by Gender: Steroid Users Omitted**

New Clients	n	%
Male	18	94.7
Female	1	5.3
<i>Total</i>	19	100
All Clients		
Male	255	84.7
Female	46	15.3
<i>Total</i>	301	100

**Table 20: Individuals in Syringe Exchange, by Age Group**

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0	1	0.2
18-19	8	8.1	21	4.7
20-24	18	18.2	55	12.3
25-29	11	11.1	50	11.2
30-34	19	19.2	73	16.3
35-39	25	25.3	102	22.8
40-44	13	13.1	82	18.3
45+	5	5.1	63	14.1
<i>Total</i>	99	100	447	100

Table 21: Individuals in Syringe Exchange by Age Group: Steroid Users Omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0	1	0.3
18-19	0	0	6	2.0
20-24	5	26.3	12	4.0
25-29	1	5.3	21	7.0
30-34	6	31.6	48	15.9
35-39	5	26.3	89	29.6
40-44	1	5.3	68	22.6
45+	1	5.3	56	18.6
<b>Total</b>	<b>19</b>	<b>100</b>	<b>301</b>	<b>100</b>

Table 22: Year to Date, by Gender &amp; Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	10	1.1	0	0	10	1.0
18-19	60	6.6	0	0	60	5.9
20-24	146	15.9	4	4.3	150	14.9
25-29	130	14.2	10	10.8	140	13.9
30-34	166	18.1	24	25.8	190	18.8
35-39	168	18.3	25	26.9	193	19.1
40-44	139	15.2	19	20.4	158	15.7
45+	97	10.6	11	11.8	108	10.7
<b>Total</b>	<b>916</b>	<b>100</b>	<b>93</b>	<b>100</b>	<b>1009</b>	<b>100</b>

Table 23: Total Syringes Provided

	This Quarter	Year to Date
Barrels	40,719	155,725
Needles	48,846	184,343

**NB:** We will no longer be reporting needle returns as it is not possible to accurately calculate them from the data available. Total Syringes include exchanges by non-attributable individuals.

## National Drug Treatment Monitoring System (NDTMS)

Quarter 4 (2006/07)

### Background

The NDTMS is the official method for measuring the extent and nature of structured drug treatment in England and Wales. The system is commissioned by the NTA and is operated through nine regional centres – corresponding to the nine government offices for the regions.

Data here are aggregated to one individual per D(A)AT. Individuals presenting in more than one D(A)AT within the quarter's time period will therefore be represented more than once in the original data. The D(A)AT referred to is D(A)AT of treatment.

### New Clients

Figures presented here for "new" clients are calculated using the triage date. Those individuals triaged within the reporting period are taken as new clients for this report. However, it should be noted that these individuals may have been triaged, or in contact with treatment services, before this period.

**Table 24: Individuals in Contact with Treatment Services, by Gender**

<b>New Clients</b>	<b>n</b>	<b>%</b>
Male	167	77.7
Female	48	22.3
<i>Total</i>	<i>215</i>	<i>100</i>
<b>All Clients</b>		
Male	2,184	73.6
Female	783	26.4
<i>Total</i>	<i>2,967</i>	<i>100</i>

**Table 25: Year to Date, by Gender**

<b>New Clients</b>	<b>n</b>	<b>%</b>
Male	590	74.1
Female	206	25.6
<i>Total</i>	<i>796</i>	<i>100</i>
<b>All Clients</b>		
Male	2247	73.7
Female	802	26.3
<i>Total</i>	<i>3049</i>	<i>100</i>

Table 26: Individuals in Contact with Treatment Services, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	22	10.2	117	3.9
18-19	10	4.7	92	3.1
20-24	10	4.7	150	5.1
25-29	29	13.5	249	8.4
30-34	46	21.4	485	16.3
35-39	48	22.3	788	26.6
40-44	38	17.7	700	23.6
45+	12	5.6	386	13.0
<b>Total</b>	215	100	2967	100

Table 27: Year to Date, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	90	11.3	185	6.1
18-19	33	4.1	85	2.8
20-24	51	6.4	301	9.9
25-29	107	13.4	552	18.1
30-34	157	19.7	747	24.5
35-39	201	25.3	680	22.3
40-44	109	13.7	339	11.1
45+	48	6.0	160	5.2
<b>Total</b>	796	100	3049	100

Table 28: Ethnicity of Individuals in Contact with Treatment Services

Ethnicity	New Clients		All Clients	
	n	%	n	%
White British	214	99.5	2,921	98.5
White Irish	0	0	5	0.2
Other White	0	0	4	0.1
White & Black Caribbean	0	0	6	0.2
White & Black African	0	0	3	0.1
Other mixed	0	0	5	0.2
Indian	0	0	1	<0.1
Pakistani	0	0	1	<0.1
Bangladeshi	0	0	1	<0.1
Other Asian	0	0	4	0.1
Caribbean	0	0	1	<0.1
African	0	0	2	0.1
Other Black	0	0	1	<0.1
Other/Unknown	1	4.5	12	0.4
<i>Total</i>	<i>215</i>	<i>100</i>	<i>2,967</i>	<i>100</i>

Table 29: Individuals in Contact with Treatment Services, by Main Drug of Use

Drug of Use	New Clients		All Clients	
	n	%	n	%
Heroin	114	53.0	2,001	67.4
Methadone	13	6.1	102	3.4
Other Opiates	5	2.3	135	4.6
Benzodiazepine	1	0.5	14	0.5
Amphetamines	7	3.3	74	2.5
Cocaine	36	16.7	209	7.0
Crack	13	6.1	124	4.2
Hallucinogens	1	0.5	3	0.1
Ecstasy	3	1.4	23	0.8
Cannabis	21	9.8	267	9.0
Solvents	0	0	5	0.2
Other/Unknown	1	0.5	10	0.3
<i>Total</i>	<i>215</i>	<i>100</i>	<i>2,967</i>	<i>100</i>

**CONNEXIONS**

Quarter 4 (2006/07)

**Background**

Connexions provide a support service for young people, aged 13-19. The Greater Merseyside Connexions Partnership provides data presented here.

**Table 30: Individuals in Contact with Connexions, by Gender**

Gender	n	%
Male	79	72.5
Female	30	27.5
<b>Total</b>	<b>109</b>	<b>100</b>

**Table 31: Year to Date, by Gender**

Gender	n	%
Male	117	75.5
Female	38	24.5
<b>Total</b>	<b>155</b>	<b>100</b>

**Table 32: Individuals in Contact with Connexions, by Age**

Age Group	n	%
16	31	28.4
17	30	27.5
18	33	30.3
19	15	13.8
<b>Total</b>	<b>109</b>	<b>100</b>

**Table 33: Year to Date, by Age**

Age Group	n	%
16	40	25.8
17	36	23.2
18	44	28.4
19	35	22.6
<b>Total</b>	<b>155</b>	<b>100</b>

**Table 34: Individuals in Contact with Connexions by Drug/Alcohol Problem**

Substance	n	%
Alcohol/Other*	34	21.2
Drugs	75	68.8
<b>Total</b>	<b>109</b>	<b>100</b>

\*"Other" is generally used to refer to solvents although this is not necessarily always the case.

**Table 35: Year to Date, by Drug/Alcohol Problem**

Substance	n	%
Alcohol/Other*	49	31.6
Drugs	106	68.4
<b>Total</b>	<b>155</b>	<b>100</b>

\*"Other" is generally used to refer to solvents although this is not necessarily always the case.

## COMBINED DATASETS

Quarter 4 (2006/07)

### Introduction

Data presented here are drawn from a combination of datasets relating to Arrest Referrals, Syringe Exchange (Agency and Pharmacy), NDTMS and Connexions. The combined data are aggregated on attributor and D(A)AT area of intervention to produce overall figures for numbers of individuals in contact with services reporting to the IAD. Figures presented here will not necessarily reflect the combined totals of data presented earlier as duplicate attributors are removed. These figures should not be taken as a measure of prevalence of problem drug users, but reflects the total number of problem drug users in contact with a range of agencies. Further information on the processes of data manipulation, aggregation and analysis is available from the IAD Manager.

**Table 36: Total Problem Drug Users reported to the IAD, by Gender and Age Group**

Gender	n	%
Male	2573	75.5
Female	833	24.5
Age Group		
Under 18	221	6.5
18-19	157	4.6
20-24	360	10.6
25-29	561	16.5
30-34	745	21.9
35-39	731	21.5
40-44	406	11.9
45+	225	6.6
<b>Total</b>	<b>3406</b>	<b>100</b>

**Table 37: Year to Date, by Gender and Age Group**

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	185	5.8	67	7.4	252	6.1
18-19	196	6.1	43	4.7	239	5.8
20-24	409	12.7	97	10.7	506	12.3
25-29	523	16.3	183	20.2	706	17.1
30-34	704	21.9	207	22.8	911	22.1
35-39	638	19.9	180	19.8	818	19.8
40-44	362	11.3	83	9.1	445	10.8
45+	196	6.1	48	5.3	244	5.9
<b>Total</b>	<b>3213</b>	<b>100</b>	<b>908</b>	<b>100</b>	<b>4121</b>	<b>100</b>

## CROSS-MATCHED DATASETS


Quarter 4 (2006/07)

Data are shown for the crossover between each type of Syringe Exchange and NDTMS, separately, during the current reported quarter. For the purposes of this analysis, known steroid users were removed as they are less likely to be accessing structured drug treatment.

For methodological reasons the crossover between all three datasets will no longer be reported. Further information is available from the IAD manager if required.

NB: Numbers in brackets refer to the total reported for that service type, with steroid users omitted. These include the numbers appearing on the crossover sections. Analyses for the crossover areas are based on D(A)AT of Syringe Exchange site.

**Fig 1: Crossover between Agency Syringe Exchange and NDTMS datasets**



**Fig 2: Crossover between Pharmacy Syringe Exchange and NDTMS datasets**

